Biologics may carry melanoma risk for patients with immune-mediated inflammatory diseasesJune 8, 2020MelanomaPsoriasisPsoriatic Arthritis
Biologics yield low rates of skin clearance in real-world psoriasis studyJune 3, 2020PsoriasisPsoriatic Arthritis
‘Loss-frame’ approach makes psoriasis patients more agreeable to treatmentMay 29, 2020PsoriasisPsoriatic Arthritis
Psoriasis patients with mental illness report lower satisfaction with physiciansMay 15, 2020PsoriasisMixed TopicsPsoriatic Arthritis
Case series suggests biologics, JAK inhibitors safe during pandemicMay 1, 2020Psoriatic ArthritisCOVID-19 UpdatesPsoriasis
Latest data on COVID-19 patients with rheumatic diseases revealed in registryApril 23, 2020COVID-19 UpdatesPediatricsPsoriasisPsoriatic Arthritis
Financial incentives affect the adoption of biosimilarsApril 16, 2020Business of MedicinePsoriatic ArthritisPsoriasis
Expert discusses her approach to using systemic agents in children and adolescents with severe skin diseaseApril 13, 2020Atopic DermatitisPediatricsPsoriasis
‘We’re in great distress here,’ infusion center CMO saysApril 10, 2020COVID-19 UpdatesPsoriatic ArthritisPsoriasis
JAK inhibitors may increase risk of herpes zosterApril 7, 2020Infectious DiseasesMixed TopicsPsoriatic ArthritisPsoriasis
Genome study examines heritability of psoriatic disease subtypesApril 2, 2020Psoriatic ArthritisPsoriasis
Rapid shift to adalimumab biosimilars in Denmark contrasts with U.S. experienceMarch 31, 2020Psoriatic ArthritisPediatricsPsoriasis
Dermatology therapies evolve as disease knowledge and investment growMarch 19, 2020Medical DermatologyAtopic DermatitisPsoriasisRare Diseases
